NO20013469L - Fremgangsmåter for glukagonsuppresjon - Google Patents

Fremgangsmåter for glukagonsuppresjon

Info

Publication number
NO20013469L
NO20013469L NO20013469A NO20013469A NO20013469L NO 20013469 L NO20013469 L NO 20013469L NO 20013469 A NO20013469 A NO 20013469A NO 20013469 A NO20013469 A NO 20013469A NO 20013469 L NO20013469 L NO 20013469L
Authority
NO
Norway
Prior art keywords
procedures
glucagon suppression
exendin
glucagon
suppression
Prior art date
Application number
NO20013469A
Other languages
English (en)
Other versions
NO20013469D0 (no
NO328077B1 (no
Inventor
Andrew Young
Bronislava Gedulin
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013469(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of NO20013469D0 publication Critical patent/NO20013469D0/no
Publication of NO20013469L publication Critical patent/NO20013469L/no
Publication of NO328077B1 publication Critical patent/NO328077B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20013469A 1999-01-14 2001-07-12 Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering. NO328077B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11638099P 1999-01-14 1999-01-14
US13201799P 1999-04-30 1999-04-30
US17536500P 2000-01-10 2000-01-10
PCT/US2000/000942 WO2000041548A2 (en) 1999-01-14 2000-01-14 Methods for glucagon suppression

Publications (3)

Publication Number Publication Date
NO20013469D0 NO20013469D0 (no) 2001-07-12
NO20013469L true NO20013469L (no) 2001-09-14
NO328077B1 NO328077B1 (no) 2009-11-23

Family

ID=27381821

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20013469A NO328077B1 (no) 1999-01-14 2001-07-12 Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering.
NO2010010C NO2010010I1 (no) 1999-01-14 2010-05-11 Exendin-4 (Exenatid)
NO2010012C NO2010012I1 (no) 1999-01-14 2010-05-20 Exennatid (Eksenatid)

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2010010C NO2010010I1 (no) 1999-01-14 2010-05-11 Exendin-4 (Exenatid)
NO2010012C NO2010012I1 (no) 1999-01-14 2010-05-20 Exennatid (Eksenatid)

Country Status (18)

Country Link
US (3) US6872700B1 (no)
EP (2) EP1658856B1 (no)
JP (1) JP2002538084A (no)
KR (2) KR20070051948A (no)
CN (1) CN100425284C (no)
AT (2) ATE460942T1 (no)
AU (2) AU770712B2 (no)
BR (1) BRPI0007823A8 (no)
CA (1) CA2356331C (no)
CY (1) CY1106347T1 (no)
DE (2) DE60032331T2 (no)
DK (1) DK1143989T3 (no)
ES (2) ES2343072T3 (no)
HK (1) HK1046105A1 (no)
NO (3) NO328077B1 (no)
NZ (1) NZ512657A (no)
PT (1) PT1143989E (no)
WO (1) WO2000041548A2 (no)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
KR100637433B1 (ko) * 2004-05-24 2006-10-20 삼성에스디아이 주식회사 발광 표시 장치
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
DE60032331T2 (de) 1999-01-14 2007-06-21 Amylin Pharmaceuticals, Inc., San Diego Exendine zur glucagon suppression
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
AU2014277804B2 (en) * 2001-07-31 2016-12-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
YU31004A (sh) * 2001-10-18 2006-08-17 Bristol-Myers Squibb Company Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja
CA2501677A1 (en) * 2002-10-22 2004-05-06 Waratah Pharmaceuticals, Inc. Treatment of diabetes
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
SI1605897T1 (sl) * 2003-03-19 2012-11-30 Lilly Co Eli Polietilen glikol povezane GLP spojine
CA2554458A1 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
PT2100904E (pt) 2004-04-23 2010-09-24 Conjuchem Biotechnologies Inc Fase sólida para utilização num método para a purificação de conjugados de albumina
BRPI0512988A (pt) 2004-07-08 2008-04-22 Novo Nordisk As método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica
EP1841448A2 (en) * 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8716221B2 (en) * 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
EP1888043A4 (en) * 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE
CA2619426C (en) 2005-08-19 2016-06-21 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
CN102827284B (zh) * 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
PT2157967E (pt) * 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
WO2009046859A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of af12198 and dago as therapeutic agents
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
AU2009262263B2 (en) * 2008-06-25 2014-08-14 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
CN104248623B (zh) 2008-09-04 2020-04-03 安米林药品有限责任公司 使用非水性载体的持续释放制剂
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
KR101112578B1 (ko) * 2009-07-16 2012-02-16 성균관대학교산학협력단 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
KR102148624B1 (ko) 2009-09-28 2020-08-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
MX2012005912A (es) 2009-11-23 2012-10-05 Amylin Pharmaceuticals Inc Conjugado de polipeptido.
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
NZ603169A (en) 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
MX345245B (es) 2010-09-28 2017-01-23 Amylin Pharmaceuticals Llc Polipeptidos manipulados que tienen duracion de accion incrementada.
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
WO2012088157A2 (en) 2010-12-22 2012-06-28 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists for islet cell transplantation
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
KR101357117B1 (ko) * 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
CN104144704B (zh) 2011-11-03 2018-03-23 西兰制药公司 Glp‑1受体激动剂肽胃泌素缀合物
CN104302772B (zh) 2012-05-18 2017-11-10 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
EP2863954A1 (en) 2012-06-21 2015-04-29 Indiana University Research and Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2652783C2 (ru) 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
SG11201602965WA (en) 2013-10-17 2016-05-30 Zealand Pharma As Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3082847A1 (en) 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
BR112017024997A2 (pt) 2015-05-22 2018-07-31 The Bot Of The Leland Stanford Junior University tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1
KR101661332B1 (ko) 2015-05-28 2016-09-29 (의료)길의료재단 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
US11123405B2 (en) 2015-12-23 2021-09-21 The Johns Hopkins University Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112018068639A2 (pt) * 2016-03-16 2019-07-30 Prolynx Llc conjugados de liberação estendida de análogos de exenatida
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂
RU2019122785A (ru) * 2016-12-22 2021-01-22 Санофи Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
KR20200019122A (ko) 2017-06-20 2020-02-21 암젠 인크 Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
AU2020233876A1 (en) 2019-03-08 2021-09-23 Amgen Inc. Growth differentiation factor 15 combination therapy
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5452284A (en) * 1992-09-14 1995-09-19 Matsushita Electric Industrial Co., Ltd. Optical recording/reproducing medium and apparatus using land and groove encoded information signals and identification signals including position information
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
EP1251502B1 (en) * 1995-10-09 2004-07-28 Matsushita Electric Industrial Co., Ltd. An optical disk with an optical barcode
CN100414612C (zh) * 1995-10-09 2008-08-27 松下电器产业株式会社 光盘
DE69732728T2 (de) * 1996-01-26 2006-04-06 Sharp K.K. Optisches Aufzeichnungsmedium und Optische Aufzeichnungs- Wiedergabevorrichtung und Verfahren zur Herstellung eines optischen Aufzeichnungsmediums
US5883958A (en) * 1996-04-01 1999-03-16 Sony Corporation Method and device for data decryption, a method and device for device identification, a recording medium, a method of disk production, and a method and apparatus for disk recording
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
JP2856390B2 (ja) * 1996-07-26 1999-02-10 株式会社日立製作所 情報記録媒体及びそれを用いた記録再生方法
DE59712555D1 (de) * 1996-06-05 2006-04-06 Roche Diagnostics Gmbh Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
DE69738507T2 (de) * 1996-07-10 2008-06-12 Hitachi, Ltd. Verfahren und System zum Datenzugriff für einen optischen Plattenspieler
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CN1311457C (zh) * 1996-12-19 2007-04-18 松下电器产业株式会社 光盘再生装置
AU739020B2 (en) 1997-01-07 2001-10-04 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JPH1131357A (ja) * 1997-07-08 1999-02-02 Pioneer Electron Corp 情報データの記録方法
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
JPH11196084A (ja) * 1997-10-31 1999-07-21 Matsushita Electric Ind Co Ltd 暗号化システム
BR9815670A (pt) 1997-11-14 2000-10-17 Amylin Pharmaceuticals Inc Compostos agonistas de exendina
DE69839021T3 (de) 1997-11-14 2013-08-08 Amylin Pharmaceuticals, Llc Neuartige exendin agonisten
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
EP1140145B2 (en) 1999-01-14 2019-05-15 Amylin Pharmaceuticals, LLC Novel exendin agonist formulations and methods of administration thereof
DE60032331T2 (de) 1999-01-14 2007-06-21 Amylin Pharmaceuticals, Inc., San Diego Exendine zur glucagon suppression
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6519213B1 (en) * 1999-06-29 2003-02-11 Oak Technology, Inc. Method and apparatus for reading data from a disk

Also Published As

Publication number Publication date
US6872700B1 (en) 2005-03-29
DE60032331T2 (de) 2007-06-21
EP1658856A1 (en) 2006-05-24
NO2010012I1 (no) 2010-06-07
US20050171019A1 (en) 2005-08-04
US7407932B2 (en) 2008-08-05
US7153825B2 (en) 2006-12-26
US20070037750A1 (en) 2007-02-15
AU2413600A (en) 2000-08-01
KR20020001719A (ko) 2002-01-09
CN100425284C (zh) 2008-10-15
KR20070051948A (ko) 2007-05-18
WO2000041548A3 (en) 2001-11-29
CA2356331A1 (en) 2000-07-20
EP1143989A2 (en) 2001-10-17
ATE347901T1 (de) 2007-01-15
HK1046105A1 (zh) 2002-12-27
ES2343072T3 (es) 2010-07-22
AU2004202293A1 (en) 2004-06-17
PT1143989E (pt) 2007-03-30
ES2278589T3 (es) 2007-08-16
WO2000041548A2 (en) 2000-07-20
NO2010010I1 (no) 2010-06-07
EP1658856B1 (en) 2010-03-17
DK1143989T3 (da) 2007-04-16
ATE460942T1 (de) 2010-04-15
BR0007823A (pt) 2001-11-20
EP1143989B1 (en) 2006-12-13
CN1347327A (zh) 2002-05-01
CY1106347T1 (el) 2011-10-12
AU770712B2 (en) 2004-02-26
EP1143989A3 (en) 2002-09-11
NO20013469D0 (no) 2001-07-12
NO328077B1 (no) 2009-11-23
DE60032331D1 (de) 2007-01-25
AU2004202293B2 (en) 2007-09-20
CA2356331C (en) 2009-10-13
DE60044041D1 (de) 2010-04-29
JP2002538084A (ja) 2002-11-12
BRPI0007823A8 (pt) 2017-03-21
NZ512657A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
NO20013469L (no) Fremgangsmåter for glukagonsuppresjon
NO20053224D0 (no) Patient controlled drug administration device.
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
NO20022334D0 (no) Ny sammensetning og anvendelse
ATE289500T1 (de) Ophtalmologische medikamentenzuführvorrichtung
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
SE0101932D0 (sv) Pharmaceutical combinations
AU2003220956A1 (en) Insulin administration apparatus
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
DE602004005564D1 (de) Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
NO20035602D0 (no) Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer
IT1311921B1 (it) Composti farmaceutici.
IL159576A0 (en) Pharmaceutical formulation for the intramuscular administration of fulvestrant
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
DK1494650T3 (da) Farmaceutisk formulering, der indeholder melatonin
FR2820311B3 (fr) Distributeur de medicament portatif
DE69934902D1 (de) Medikament gegen drogenabhängigkeit
GB0212790D0 (en) Medicament for the treatment of diabetes
ITUD20030196A1 (it) Procedimento per la preparazione di dosaggi farmaceutici contenenti molteplici principi attivi.
RU2001109481A (ru) Антиангинальное средство
SE0000332D0 (sv) New use
IT1312082B1 (it) Derivati morfinoidi, procedimento per la loro preparzione e loroimpiego terapeutico.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: BYETTA; NAT. REG. NO/DATE: EU/1/06/362/001-004/NO 20061120; FIRST REG. NO/DATE: EU , EU/1/06/362/001-004 20061120

Spc suppl protection certif: 2010010

Filing date: 20100511

Free format text: PRODUCT NAME: BYETTA; NAT. REG. NO/DATE: EU/1/06/362/001-4/NO 20061120; FIRST REG. NO/DATE: EU/1/06/362/001-004 20061120

Spc suppl protection certif: 2010012

Filing date: 20100520

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA PHARMACEUTICALS LP, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA PHARMACEUTICALS LP, US

MK1K Patent expired